Antiviral pioneer Gilead Sciences is expected to report fourth-quarter earnings results on Tuesday after the closing bell. A Zacks Rank #3 (Hold) stock, Gilead surpassed earnings estimates in three of the past four quarters. With the stock showing momentum this year, is GILD a buy ahead of the release?
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Analysts expect the company to post a profit of $1.83 per share, reflecting a -3.7% decline versus the same quarter in the prior year. Estimates for the quarter have come down slightly over the past 60 days. Revenues are projected to rise 0.07% to $7.57 billion.
The drug developer posted a trailing four-quarter average earnings surprise of 7.8%. Its market-leading HIV franchise has fueled top-line growth. Gilead GILD has also diversified into the lucrative oncology market.
Shares remain undervalued relative to industry peers. The stock is outperforming in 2026 with a 22% return year-to-date.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-09 | |
| Nov-06 | |
| Nov-06 | |
| Nov-05 | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Nov-02 | |
| Nov-01 | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite